Abstract
In this retrospective case-control study, we compared the number of circulating lymphocyte subsets among 31 healthy controls, 18 naïve and 40 antiretroviral-treated HIV patients, 28 untreated and 18 treated relapsing-remitting multiple sclerosis (MS) patients. Lymphocyte subsets were no different between untreated MS patients and controls. Untreated and treated MS had a lower CD8+ count and a higher CD4+ number compared to untreated and treated HIV patients except similar CD4+ number between treated MS and HIV patients. CD4/CD8 ratio was lower in female HIV non-responders and in relapsing MS women compared, respectively, to female HIV responders and remitting MS women, and there were no differences in men.
Keywords:
CD4+ count; HIV positive dermatological patients; Multiple Sclerosis; circulating lymphocytes; gender.
MeSH terms
-
Adult
-
Anti-HIV Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active
-
Biomarkers / analysis
-
CD4 Lymphocyte Count
-
CD4-CD8 Ratio
-
CD4-Positive T-Lymphocytes / immunology*
-
CD4-Positive T-Lymphocytes / virology
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / virology
-
Case-Control Studies
-
Female
-
Glatiramer Acetate / therapeutic use
-
HIV Infections / diagnosis*
-
HIV Infections / drug therapy
-
HIV Infections / immunology
-
HIV Infections / virology
-
Humans
-
Immunologic Factors / therapeutic use*
-
Immunophenotyping
-
Interferon-beta / therapeutic use
-
Male
-
Middle Aged
-
Multiple Sclerosis, Relapsing-Remitting / diagnosis*
-
Multiple Sclerosis, Relapsing-Remitting / drug therapy
-
Multiple Sclerosis, Relapsing-Remitting / immunology
-
Multiple Sclerosis, Relapsing-Remitting / virology
-
Prognosis
-
Retrospective Studies
-
Sex Factors
-
Viral Load / drug effects
Substances
-
Anti-HIV Agents
-
Biomarkers
-
Immunologic Factors
-
Glatiramer Acetate
-
Interferon-beta